Predicting Survival for Patients with Malignant Pleural Effusion: Development of the CONCH Prognostic Model
Xin Zhang,Feng-Shuang Yi,Huan-Zhong Shi
DOI: https://doi.org/10.2147/CMAR.S305223
2021-06-14
Cancer Management and Research
Abstract:Xin Zhang *, Feng-Shuang Yi *, Huan-Zhong Shi Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China *These authors contributed equally to this work Correspondence: Huan-Zhong Shi; Feng-Shuang Yi Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongti Nanlu, Chao-Yang District, Beijing, 100020, People's Republic of China Tel/Fax +86 10 85231890 Email ; Background: Malignant pleural effusion (MPE) is a frequent complication of advanced malignancies that leads to a poor quality of life and limits treatment options. Objective: The objective of this study was to identify biomarkers of survival in patients with MPE, which will greatly facilitate the clinical management of this complication. Methods: This retrospective study recruited patients who had been pathologically diagnosed with MPE, regardless of the type of primary cancer, at Beijing Chao-Yang Hospital over 158 months. Demographic, clinical, hematological, and pleural fluid data were collected and analyzed as potential predictors of survival, and a new predictive model was developed based on Cox and logistic regression analyses. Results: In our alternative prognostic model (n = 281), four routinely detected variables, namely, carcinoembryonic antigen (CEA) level, monocyte count, N-terminal pro B-type natriuretic peptide (NT-pro-BNP) level, and pleural effusion chloride level on admission, were identified as predictors (the CONCH prognostic score). Patients were divided into three prognosis subgroups based on risk stratification, with median survival periods of 17, 11, and 5 months, respectively. In comparison with the low-risk group, patients in the medium- and high-risk groups showed significantly poorer survival (medium-risk group: hazard ratio [HR], 1.586; 95% confidence interval [CI], 1.047– 2.402; P = 0.029; high-risk group: HR, 4.389; 95% CI, 2.432– 7.921; P < 0.001). Conclusion: Four routinely detected variables were used to develop the CONCH scoring system, which was confirmed to be an accurate prognostic score for patients with MPE. This system can guide the selection of interventions and management for MPE. Keywords: malignant pleural effusion, prognosis, CEA, monocyte, NT-pro-BNP Malignant pleural effusion (MPE) is a frequently occurring complication associated with poor patient outcomes, high mortality rates, and increased healthcare costs. The most common complaint in patients with MPE is dyspnea, which is prior to chest distress and cough. 1 Metastatic disease is the leading cause of MPE, among which most commonly observed is lung cancer, followed by breast cancer. Mesothelioma, which accounts for the majority of primary pleural tumors leading to the formation of MPE, 2 has attracted wide attention and is a challenging diagnosis. Cytological examination of pleural fluid and pleural biopsy are the two main diagnostic methods for mesotheliomas. 3 , 4 More recently, immunohistochemistry (IHC) using soluble mesothelin-related peptide (SMRP) and the combination of MTAP and BAP1 have been confirmed to be useful for diagnosis. 5 , 6 In addition, based on the multiple chromosomal imbalances in a series of malignant peritoneal mesothelioma cases, Serio et al hypothesized that the loss of function of ubiquitination, as well as of the defensins, could play an important role in the initial development and subsequent progression of mesothelioma. 7 The treatment strategy for patients with MPE remains palliative, and mainly aims to relieve symptoms and improve patients' quality of life. At present, pleurectomy is usually replaced by less invasive management procedures such as pleurodesis and indwelling pleural catheters, and trials for some novel technologies are underway. 8–10 Determination of the most appropriate treatment is challenging when the precise survival of certain patients is unpredictable, since patients with longer life expectancy may adopt more positive treatment options. Predictive indicators for many malignant diseases have been thoroughly studied over the past few decades. However, evaluation of the prognosis of patients with MPE remains challenging. Psallidas et al reported the pleurodesis response markers in MPE (PROMISE) for assessments of survival; however, these markers were largely associated with prio -Abstract Truncated-
oncology